Acyclovir Capsule
Product Images NDC 51407-852

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Acyclovir (NDC 51407-852). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-852-01lb (Acyclovir Caps)

This text appears to be a description of a medication called Acyclovir. The medication is available in capsule form, with each capsule containing 200 mg of Acyclovir. It is recommended to store the capsules in a tight container, away from light and moisture. The medication should be kept out of the reach of children. The recommended storage temperature is between 20°C and 25°C (68°F and 77°F).*

FDA Label Image

Structural Formula (Acy03 0000 01)

FDA Label Image

Table 1 (Acy03 0000 02)

This text provides information about the pharmacokinetic characteristics of Acyclovir, a medication used to treat viral infections. The table shows the range for various parameters, including plasma protein binding (9% to 1033%), plasma elimination half-life (25 to 1033 hours), and average oral bioavailability (10% to 20%). It also mentions that bioavailability decreases with increasing dose.*

FDA Label Image

Table 2 (Acy03 0000 03)

This text provides information about the peak and trough concentrations of Acyclovir at steady state for different doses (200 mg, 400 mg, and 800 mg). The table shows the values for Coax (presumably Cmax, the peak concentration) and C irough (presumably Cmin, the trough concentration) in meg/mL for each dose.*

FDA Label Image

Table 3 (Acy03 0000 04)

Dosage modification for renal impairment is provided in Table 3. The table presents the normal dosage, adjusted dosage regimen, creatinine clearance, dose in milligrams (mg), and dosing interval for different scenarios. The dosing intervals vary based on creatinine clearance levels. The adjusted dosage regimen for each scenario is described in terms of the frequency of administration (every 4, 8, or 12 hours) and the recommended dosage (200, 400, or 800 mg). The text provides specific information regarding dosage modification for renal impairment.*

FDA Label Image

Imprint Cti 114 (Acy03 0000 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.